In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

iTeos Therapeutics, Inc. (ITOS). Financial results for the second quarter of 2020

02.09.2020

Non-GAAP net loss - $29.49 per share.
Cash position - $136.9 million.